Study supports efficacy and safety of lung-selective nanotherapy against SARS-CoV-2 infection
| Date | 8th, Oct 2021 |
|---|---|
| Source | News Medical - Scientific News Websites |
DESCRIPTION
A new preprint shows the potential role of a host protease cathepsin L inhibitor, which mediates viral entry into the host cell by its effect on the viral spike protein.